A PHASE 3 OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY AND EFFICACY OF ORALLY ADMINISTERED NNZ-2591 IN PEDIATRIC PARTICIPANTS WITH PHELAN-MCDERMID SYNDROME

Registry ID

NEU-2591-PMS-302

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NEUREN PHARMACEUTICALS LTD.

Last update

2026-04-13

Conditions

• NEURODEGENERATIVE DISEASES

Related clinical trials

• THE BRAIN-EYE AMYLOID MEMORY (BEAM) STUDY: VALADATION OF OCULAR MEASURES AS POTENTIAL BIOMARKERS FOR EARLY DETECTION AMYLOID AND NEURODEGENERATION

View on source registry